Search Result

Results for "

quinazoline-derivative

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (13) Akt (1) Amyloid-β (1) Apoptosis (1) Autophagy (2) Biochemical Assay Reagents (1) Cholinesterase (ChE) (1) EGFR (1) ERK (1) Isotope-Labeled Compounds (2) Mitophagy (2) VEGFR (1)
By Research Areas:	Cancer (4) Cardiovascular Disease (10) Endocrinology (10) Metabolic Disease (6) Neurological Disease (1)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Drug Derivative

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0098

Doxazosin 1 Publications Verification UK 33274	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Doxazosin (UK 33274) is a quinazoline-derivative that selectively antagonizes postsynaptic α1-adrenergic receptors.

HY-B0098A

Doxazosin mesylate 1 Publications Verification UK 33274 mesylate	Adrenergic Receptor Autophagy Mitophagy	Cardiovascular Disease Endocrinology Cancer
Doxazosin mesylate (UK 33274 mesylate) is a quinazoline-derivative that selectively antagonizes postsynaptic α1-adrenergic receptors.

HY-B0371F

Terazosin hydrochloride Maximum Cited Publications 6 Publications Verification	Adrenergic Receptor	Cardiovascular Disease Metabolic Disease Endocrinology
Terazosin hydrochloride is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .

HY-W010778

N-(3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-iodoquinazolin-4-amine	Biochemical Assay Reagents	Others
N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-iodo-quinazolin-4-amine is a quinazoline derivative that has also been used in the design, synthesis and biological evaluation of quinazoline-phosphoramidate mustard conjugates as anticancer drugs.

HY-B0098S

Doxazosin-d8 UK 33274-d₈	Isotope-Labeled Compounds Adrenergic Receptor	Cardiovascular Disease Endocrinology
Doxazosin-d₈ is a deuterium labeled Doxazosin (UK 33274). Doxazosin is a quinazoline-derivative that selectively antagonizes postsynaptic α1 adrenergic receptors[1].

HY-B0098AR

Doxazosin (mesylate) (Standard)	Adrenergic Receptor Autophagy Mitophagy	Cardiovascular Disease Endocrinology Cancer
Doxazosin (mesylate) (Standard) is the analytical standard of Doxazosin (mesylate). This product is intended for research and analytical applications. Doxazosin mesylate (UK 33274) is a quinazoline-derivative that selectively antagonizes postsynaptic α1-adrenergic receptors.

HY-131449

Terazosin dimer impurity dihydrochloride	Adrenergic Receptor	Others
Terazosin dimer impurity dihydrochloride, a dimer of Terazosin, is an impurity of Terazosin. Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist .

HY-106554

Trimazosin	Adrenergic Receptor	Cardiovascular Disease
Trimazosin is an orally active, quinazoline derivative which is structurally related to prazosin. Trimazosin shows hypotensive effect by selectively block α1-adrenoceptors .

HY-106554A

Trimazosin hydrochloride hydrate	Adrenergic Receptor	Cardiovascular Disease
Trimazosin hydrochloride hydrate is an orally active, quinazoline derivative which is structurally related to prazosin. Trimazosin shows hypotensive effect by selectively block α1-adrenergic receptor .

HY-B0371

Terazosin	Adrenergic Receptor	Cardiovascular Disease Metabolic Disease Endocrinology
Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .

HY-B0371A

Terazosin hydrochloride dihydrate Maximum Cited Publications 6 Publications Verification	Adrenergic Receptor	Cardiovascular Disease Metabolic Disease Endocrinology
Terazosin hydrochloride dihydrate is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride dihydrate works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride dihydrate has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .

HY-B0371S

Terazosin-d8	Isotope-Labeled Compounds Adrenergic Receptor	Metabolic Disease Endocrinology
Terazosin-d₈ is deuterium labeled Terazosin. Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment[1][2][3].

HY-B0371FR

Terazosin (hydrochloride) (Standard)	Adrenergic Receptor	Cardiovascular Disease Metabolic Disease Endocrinology
Terazosin (hydrochloride) (Standard) is the analytical standard of Terazosin (hydrochloride). This product is intended for research and analytical applications. Terazosin hydrochloride is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .

HY-101931

hVEGF-IN-1	VEGFR	Cancer
hVEGF-IN-1, a quinazoline derivative, could specifically bind to the G-rich sequence in the internal ribosome entry site A (IRES-A) and destabilize the G-quadruplex structure. hVEGF-IN-1 binds to the IRES-A (WT) with a K_d of 0.928 μM in SPR experiments. hVEGF-IN-1 could hinder tumor cells migration and repress tumor growth by decreasing VEGF-A protein expression .

HY-B0371AR

Terazosin (hydrochloride dihydrate) (Standard)	Adrenergic Receptor	Metabolic Disease Endocrinology
Terazosin (hydrochloride dihydrate) (Standard) is the analytical standard of Terazosin (hydrochloride dihydrate). This product is intended for research and analytical applications. Terazosin hydrochloride dihydrate is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride dihydrate works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride dihydrate has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .

HY-164489

KU004	EGFR Akt ERK Apoptosis	Cancer
KU004 is a potent dual EGFR/HER2 inhibitor with anticancer effects. KU004 inhibits the proliferation of human breast cancer SKBR3 cells by inducing G1 phase arrest. KU004 blocks the activation of HER2, EGFR and downstream Akt and Erk pathways and induces cell Apoptosis mainly via the extrinsic pathway. KU004 is a quinazoline derivative .

HY-161512

hAChE/hBACE-1-IN-4	Cholinesterase (ChE) Amyloid-β	Neurological Disease
hAChE/hBACE-1-IN-4 (compound AK-2) is a quinazoline derivative. hAChE/hBACE-1-IN-4 shows significant inhibitory activity against hAChE and hBACE-1 enzymes (hAChE, IC₅₀=0.283 μM; hBACE-1, IC₅₀=0.231 μM). hAChE/hBACE-1-IN-4 has the potential to inhibit Aβ aggregation. hAChE/hBACE-1-IN-4 has non-neurotoxicity , blood-brain barrier permeability and oral activity. hAChE/hBACE-1-IN-4 can be used in Alzheimer's disease research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0098

Doxazosin 1 Publications Verification UK 33274	Classification of Application Fields Disease Research Fields Endocrinology	Adrenergic Receptor
Doxazosin (UK 33274) is a quinazoline-derivative that selectively antagonizes postsynaptic α1-adrenergic receptors.

HY-B0371

Terazosin	Classification of Application Fields Disease Research Fields Endocrinology	Adrenergic Receptor
Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .

Cat. No.	Product Name	Chemical Structure

HY-B0098S

Doxazosin-d8
Doxazosin-d₈ is a deuterium labeled Doxazosin (UK 33274). Doxazosin is a quinazoline-derivative that selectively antagonizes postsynaptic α1 adrenergic receptors[1].

HY-B0371S

Terazosin-d8
Terazosin-d₈ is deuterium labeled Terazosin. Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment[1][2][3].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

quinazoline-derivative

Inhibitors & Agonists

NaturalProducts

Isotope-Labeled Compounds

Natural
Products